Tasca Therapeutics

Oncology

News and advice from an investor-CEO, with Milenko Cicmil

pharmaphorum caught up with Milenko Cicmil to talk about Tasca Therapeutics’ news at LSX: their first patient dosed for lead asset CP-383.

News

UK says it has hit target on commercial trial set-up times

The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in industry-backed studies.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks